ProQR Therapeutics N.V.
PRQR
$2.26
$0.052.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -36.17% | -1.56% | 29.86% | 183.34% | 417.41% |
| Total Other Revenue | 6.79% | 2.46% | -- | -- | 305.56% |
| Total Revenue | -35.13% | -1.38% | 33.96% | 193.51% | 413.98% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -35.13% | -1.38% | 33.96% | 193.51% | 413.98% |
| SG&A Expenses | 68.54% | -9.18% | -18.43% | 0.03% | -28.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.04% | 18.42% | 15.20% | 46.38% | -1.05% |
| Operating Income | -258.77% | -29.84% | -8.51% | -19.11% | 59.60% |
| Income Before Tax | -343.39% | -27.64% | -68.19% | -49.96% | 64.34% |
| Income Tax Expenses | 109.48% | -- | -100.00% | -- | -371.12% |
| Earnings from Continuing Operations | -377.04% | -27.58% | -68.03% | -51.10% | 66.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -377.04% | -27.58% | -68.03% | -43.42% | 66.70% |
| EBIT | -258.77% | -29.84% | -8.51% | -19.11% | 59.60% |
| EBITDA | -322.44% | -33.09% | -8.10% | -20.15% | 65.23% |
| EPS Basic | -269.58% | 1.18% | -37.28% | -42.24% | 66.98% |
| Normalized Basic EPS | -244.12% | 1.10% | 10.47% | -10.18% | 64.79% |
| EPS Diluted | -283.66% | -3.24% | -37.28% | -43.29% | 67.37% |
| Normalized Diluted EPS | -244.12% | 1.10% | 10.47% | -10.18% | 64.79% |
| Average Basic Shares Outstanding | 28.99% | 29.09% | 22.42% | 0.84% | 0.90% |
| Average Diluted Shares Outstanding | 28.99% | 29.09% | 22.42% | 0.84% | 0.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |